Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tuna Mutis

Showing results (91-100 of 110) with videos related to

Pageof 11
Sort By:
Journal of Immunology (Baltimore, Md. : 1950)|December 29, 2010
Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumorsMichel de Weers, Yu-Tzu Tai, Michael S van der Veer, et al.
Blood|August 19, 2025
A T-cell-based metric of immune age predicts outcomes in older patients with myeloma receiving daratumumab-based therapyWassilis S C Bruins, Febe Smits, Carolien Duetz, et al.
Haematologica|February 23, 2019
CD20 and CD37 antibodies synergize to activate complement by Fc-mediated clusteringSimone C Oostindie, Hilma J van der Horst, Margaret A Lindorfer, et al.
Leukemia|May 28, 2020
Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumabTineke Casneuf, Homer C Adams, Niels W C J van de Donk, et al.
Hemasphere|April 20, 2026
Monocyte-mediated metabolic rewiring via CD31-CD38 interactions promotes growth and drug-resistance in multiple myelomaRamin Raoof, Giada Dal Collo, Helga Simon-Molas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 14, 2017
Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with DaratumumabJakub Krejcik, Kris A Frerichs, Inger S Nijhof, et al.
Blood|June 2, 2012
Reconstructing the human hematopoietic niche in immunodeficient mice: opportunities for studying primary multiple myelomaRichard W J Groen, Willy A Noort, Reinier A Raymakers, et al.
Science Translational Medicine|December 8, 2021
Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistenceAfroditi Katsarou, Maria Sjöstrand, Jyoti Naik, et al.
Blood Advances|January 8, 2024
Distinct peripheral T-cell and NK-cell profiles in HGBL-MYC/BCL2 vs patients with DLBCL NOSA Vera de Jonge, Carolien Duetz, Wassilis S C Bruins, et al.
Blood Cancer Journal|April 29, 2020
DuoHexaBody-CD37<sup>®</sup>, a novel biparatopic CD37 antibody with enhanced Fc-mediated hexamerization as a potential therapy for B-cell malignanciesSimone C Oostindie, Hilma J van der Horst, Laurens P Kil, et al.
Pageof 11

Showing results (91-100 of 110) with videos related to

Sort By:
Pageof 11
Journal of Immunology (Baltimore, Md. : 1950)|December 29, 2010
Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumorsMichel de Weers, Yu-Tzu Tai, Michael S van der Veer, et al.
Blood|August 19, 2025
A T-cell-based metric of immune age predicts outcomes in older patients with myeloma receiving daratumumab-based therapyWassilis S C Bruins, Febe Smits, Carolien Duetz, et al.
Haematologica|February 23, 2019
CD20 and CD37 antibodies synergize to activate complement by Fc-mediated clusteringSimone C Oostindie, Hilma J van der Horst, Margaret A Lindorfer, et al.
Leukemia|May 28, 2020
Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumabTineke Casneuf, Homer C Adams, Niels W C J van de Donk, et al.
Hemasphere|April 20, 2026
Monocyte-mediated metabolic rewiring via CD31-CD38 interactions promotes growth and drug-resistance in multiple myelomaRamin Raoof, Giada Dal Collo, Helga Simon-Molas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 14, 2017
Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with DaratumumabJakub Krejcik, Kris A Frerichs, Inger S Nijhof, et al.
Blood|June 2, 2012
Reconstructing the human hematopoietic niche in immunodeficient mice: opportunities for studying primary multiple myelomaRichard W J Groen, Willy A Noort, Reinier A Raymakers, et al.
Science Translational Medicine|December 8, 2021
Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistenceAfroditi Katsarou, Maria Sjöstrand, Jyoti Naik, et al.
Blood Advances|January 8, 2024
Distinct peripheral T-cell and NK-cell profiles in HGBL-MYC/BCL2 vs patients with DLBCL NOSA Vera de Jonge, Carolien Duetz, Wassilis S C Bruins, et al.
Blood Cancer Journal|April 29, 2020
DuoHexaBody-CD37<sup>®</sup>, a novel biparatopic CD37 antibody with enhanced Fc-mediated hexamerization as a potential therapy for B-cell malignanciesSimone C Oostindie, Hilma J van der Horst, Laurens P Kil, et al.
Pageof 11